Aurobindo Pharma

• 

  Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

  The USFDA approval for Aurobindo Pharma's first metered-dose inhaler takes its cumulative ANDA approvals to 596, strengthening its complex product portfolio.

• 

  Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

  Aurobindo Pharma informed exchanges that the US FDA inspection at Lannett’s Seymour facility concluded with four procedural observations

• 

  Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven

  Aurobindo Pharma reported a 25.2% year-on-year (YoY) rise in consolidated net profit to Rs 1,033 crore, while revenue increased 16.3% to Rs 9,150 crore.

• 

  Aurobindo Pharma Clears Major US Regulatory Hurdle In $250 Million Lannett Deal

  The Hyderabad-based drugmaker had agreed to acquire Lannett in July 2025 for $250 million as part of its strategy to strengthen its presence in the US generics market.

• 

  Aurobindo Pharma Shares In Focus After Q3 Results; This Brokerage Maintains A Bullish View — More Details Inside

  The brokerage noted that Aurobindo is expected to complete the Rs 2,075 crore acquisition of Lannett in Q1 FY27, which may add nearly 7% to FY27 US revenue growth.

• 

  Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List

  Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.

• 

  Five Stocks To Buy: Divi's Labs, Aurobindo Pharma, Britannia And More

  Multiple experts are converging on select pharma, FMCG, media, and financial services counters. Key names on today’s radar include Divi’s Laboratories, Aurobindo Pharma, and Britannia Industries.

• 

  Aurobindo Pharma: Motilal Oswal Maintains 'Buy' Citing Multiple Growth Triggers, Sees Upto 18% Upside

  Aurobindo Pharma’s diversification and policy tailwinds signal potential upside, says Motilal Oswal, retaining 'Buy' call.

• 

  Aurobindo's China Dependence Persists As Penicillin-G Ramp-Up Stalls, Macquarie Remains Bearish

  Aurobindo continues to be rated 'underperform' by the brokerage, with a target price of Rs 1,010.

• 

  Aurobindo Pharma Incurring Loss At China Plant, Aims Break-Even By Q4

  The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals

• 

  Lupin, Fortis Among Axis Securities Top 'Buy' In Pharma, Healthcare Space; Q2 Review — Details Inside

  The healthcare space continues to outperform and pharma sector impacted by US generics in Q2, adds the brokerage.

• 

  LIC, Mankind Pharma, Aurobindo Pharma, Godrej Properties, Birlasoft, Metropolis, Symphony & More Q2 Review

  HDFC Securities recommends 'Add' rating for LIC, Aurobindo Pharma, Star Cement, Metropolis, Godrej Properties 'Buy' Symphony, Astral, 'Reduce' Alkyl Amines, Clean Science - here's why

• 

  Aurobindo, Sun Pharma, Blue Star, Britannia, Delhivery Q2 Results Today — Earnings Estimates

  Other big names announcing results include Piramal Pharma.

• 

  Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks

  Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.

• 

  Aurobindo Pharma Eyes 'Significant Portion' Of $7 Billion Osteoporosis Drug Market

  The company is preparing for regulatory filings in key markets like the US and EU starting January 2026.